Novo Nordisk CEO signals openness to direct New York Stock Exchange listing to replace ADRs
AI Market Summary
Novo Nordisk's CEO signaled openness to a direct NYSE listing to replace the ADR structure, reflecting a long-term shift in the shareholder base toward U.S. investors. While management stressed there is no active process, the comment can raise focus on governance, index/ownership dynamics, and liquidity. The backdrop of a sharp share drawdown and intensifying obesity-drug competition underscores sensitivity to investor confidence.
Impact level
● Medium
Affected assets
NCSKNVO2USD/USDT-3.16%
AI Insight · NCSKNVO2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Novo Nordisk CEO Maziar Mike Doustdar said the company is open to a direct listing on the New York Stock Exchange to replace its existing American depositary receipts, the Financial Times reported. He said the move would reflect a shift in the company’s investor base over the past 20 years away from Scandinavia and toward the United States. Novo’s shares have fallen more than 70% from their peak, while Eli Lilly’s have risen. Lilly’s weight-loss drug Zepbound is expected to outsell Novo’s Wegovy this year by more than $7 billion.
